16 completed, 12 recruiting, 8 terminated, 7 active not recruiting. 27 Phase 2, 16 Phase 1, 6 Not applicable, 5 Phase 3, 2 Phase 4.
Follow Chronic Graft Versus Host Disease: new trials by email Literature Review of Chronic Graft Versus Host Disease trials Research Report on Chronic Graft Versus Host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host Disease Biospecimen Collection, Mindfulness Relaxation, Survey Administration - Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Not applicable | Recruiting | City of Hope Medical Center | 17 | 2027-03-01 | 2026-10-16 |
| A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD) Belumosudil - Chronic Graft Versus Host Disease | Phase 4 | Not yet recruiting | Sanofi | 26 | 2026-10-30 | 2026-10-23 |
| A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease Belumosudil, Best available therapy (BAT) - Chronic Graft Versus Host Disease | Phase 3 | Not yet recruiting | Sanofi | 356 | 2026-09-07 | 2026-09-15 |
| Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants Belumosudil - Chronic Graft Versus Host Disease | Phase 1 | Not yet recruiting | Sanofi | 58 | 2026-08-06 | 2026-07-24 |
| Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease Dental Cleaning, Dental Plaque sampling - Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease | Not applicable | Recruiting | Fred Hutchinson Cancer Center | 45 | 2026-05-12 | 2026-10-21 |
| Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD Belumosudil - Chronic Graft Versus Host Disease | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 8 | 2026-02-09 | 2026-08-27 |
| A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) Belumosudil - Chronic Graft Versus Host Disease | Phase 2 | Recruiting | Sanofi | 37 | 2025-12-02 | 2026-09-22 |
| Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD Fostamatinib, Ruxolitinib - Chronic Graft Versus Host Disease | Phase 1 | Recruiting | Stefanie Sarantopoulos, MD, PhD. | 30 | 2025-10-29 | 2026-01-22 |
| Axatilimab for Sclerotic Chronic Graft-versus-Host Disease Axatilimab, Biospecimen Collection, Questionnaire Administration - Chronic Graft Versus Host Disease | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2025-08-06 | 2026-09-24 |
| Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy Gecacitinib Hydrochloride Tablets - Chronic Graft Versus Host Disease | Phase 1 / Phase 2 | Recruiting | Yujun DONG | 24 | 2025-06-30 | 2025-06-10 |
| Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy Belumosudil - Chronic Graft Versus Host Disease | Phase 2 | Withdrawn | Kadmon, a Sanofi Company | 2025-06-16 | 2026-02-12 | |
| Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease Axatilimab, Extracorporeal Photopheresis - Chronic Graft Versus Host Disease, cGVHD | Phase 2 | Recruiting | University of Miami | 49 | 2025-05-05 | 2026-06-22 |
| Upfront Ruxolitinib for Chronic Graft-vs-host Disease Ruxolitinib - Chronic Graft Versus Host Disease | Phase 1 | Terminated | Children's Hospital Medical Center, Cincinnati | 1 | 2025-02-19 | 2026-02-25 |
| Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant Echocardiography Test, Ibrutinib - Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Terminated | Mayo Clinic | 2 | 2024-12-13 | 2026-05-22 |
| A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies Belumosudil - Chronic Graft Versus Host Disease | Phase 4 | Completed | Sanofi | 6 | 2024-12-04 | 2026-05-27 |
| BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) Belumosudil, Fluticasone, Azithromycin - Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 45 | 2024-05-31 | 2026-06-10 |
| Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD) Additional blood sample, cGVHD target tissue biopsy - Chronic Graft Versus Host Disease | Not applicable | Recruiting | University Hospital, Bordeaux | 70 | 2024-05-21 | 2026-07-16 |
| A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease TQ05105 tablets - Chronic Graft Versus Host Disease | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 65 | 2024-05-07 | 2026-08-26 |
| Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy - Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder | Phase 1 | Suspended | City of Hope Medical Center | 27 | 2024-02-19 | 2025-11-13 |
| Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease Belumosudil, Rituximab - Chronic Graft Versus Host Disease | Phase 2 | Suspended | Northside Hospital, Inc. | 25 | 2024-01-29 | 2026-10-16 |
Showing 20 of 52. Sign in to see all of them.
Bronchiolitis Obliterans Syndrome (52) · Graft vs Host Disease (6) · Bronchiolitis Obliterans (3) · Anemia, Sickle Cell (1) · Autoimmune Diseases (1) · Dermatomyositis (1) · Fasciitis (1) · Hematologic Diseases (1) · Immune System Diseases (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Diseases (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Pemphigoid, Benign Mucous Membrane (1)
Bronchial Diseases (52) · Bronchiolitis (52) · Bronchitis (52) · Lung Diseases, Obstructive (52) · Organizing Pneumonia (52) · Respiratory Tract Diseases (52) · Immune System Diseases (51) · Lung Diseases (51) · Bronchiolitis Obliterans (49) · Graft vs Host Disease (46) · Hemic and Lymphatic Diseases (4) · Hematologic Diseases (3) · Musculoskeletal Diseases (3) · Cardiovascular Diseases (2) · Connective Tissue Diseases (2)
belumosudil (11) · KD025 (5) · Prednisone (4) · Specimen Handling (4) · ibrutinib (4) · Photopheresis (3) · axatilimab (2) · montelukast (2) · ruxolitinib (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Abatacept (1) · Azithromycin (1) · Biopsy (1) · Bortezomib (1)
Fred Hutchinson Cancer Center (9) · Sanofi (6) · City of Hope Medical Center (4) · Dana-Farber Cancer Institute (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · National Cancer Institute (NCI) (2) · Pharmacyclics LLC. (2) · Actelion (1) · Beth Israel Deaconess Medical Center (1) · Children's Hospital Medical Center, Cincinnati (1) · Chinese Academy of Medical Sciences (1) · Duke University (1) · Emory University (1) · Gilead Sciences (1) · Gruppo Italiano Trapianto di Midollo Osseo (1)
United States (37) · China (9) · France (9) · Italy (9) · Canada (8) · Germany (8) · Spain (8) · Israel (6) · United Kingdom (6) · Austria (5) · South Korea (5) · Australia (4) · Belgium (4) · Netherlands (4) · Greece (3)
Stephanie Lee (4) · Amandeep Salhotra (3) · John Koreth, MBBS, DPhil (2) · Adela Cardones, MD (1) · Amandeep Salhotra, MD (1) · Amin Alousi, MD (1) · Armin Rashidi, MD, PhD (1) · Attilio Olivieri, MD (1) · Chenyu Lin, MD (1) · Chunhua Zhao, MD,PHD (1) · Corey Cutler, MD, MPH (1) · Daniel R Couriel (1) · Daniele D'Ambrosio, MD, PhD (1) · Gauri Sunkersett (1)
PMID 10387937, PMID 10845940, PMID 10997973, PMID 11222360, PMID 11509929, PMID 11981005, PMID 12070007, PMID 12931119, PMID 14512314, PMID 15142114, PMID 15251978, PMID 15292060, PMID 15613541, PMID 16046530, PMID 16239908, PMID 16551963, PMID 16788100, PMID 16946302, PMID 17549053, PMID 17671231, PMID 19597425, PMID 21791424, PMID 22500839, PMID 23353804, PMID 23861248, PMID 24315843, PMID 24820310, PMID 25385601, PMID 25395505, PMID 25687558, PMID 25715403, PMID 25985915, PMID 26527676, PMID 2670000, PMID 26983850, PMID 27436361, PMID 28495794, PMID 29281578, PMID 29549175, PMID 30237265, PMID 3042041, PMID 30518977, PMID 31332045, PMID 34126278, PMID 34265047, PMID 34649279, PMID 35475885, PMID 36189324, PMID 36608310, PMID 36862975
P30CA015704 (3), P30CA033572 (2), 2015 (1), 2017 (1), 2023 (1), P30CA042014 (1), R01CA118953 (1), R01CA183559 (1), U01CA118953 (1)